Overview This page contains the latest trade data of Erythromycin, derivatives, in bulk, salts. In 2023, Erythromycin, derivatives, in bulk, salts were the world's 2829th most traded product, with a total trade of $513M. Between 2022 and 2023 the exports of Erythromycin, derivatives, in bulk, salts grew by 5.1%, from $488M to $513M. Trade in Erythromycin, derivatives, in bulk, salts represent 0.0023% of total world trade.
Erythromycin, derivatives, in bulk, salts are a part of Antibiotics.
Exports In 2023 the top exporters of Erythromycin, derivatives, in bulk, salts were China ($314M), India ($81.8M), United States ($57M), Netherlands ($10.9M), and Spain ($8.79M).
Imports In 2023 the top importers of Erythromycin, derivatives, in bulk, salts were India ($178M), Japan ($32.7M), Croatia ($30.2M), Pakistan ($19.4M), and United States ($17.9M).
Ranking Erythromycin, derivatives, in bulk, salts ranks 1569th in the Product Complexity Index (PCI).
Description Erythromycin is primarily used as an antibiotic. It is also used as a drug to treat some bacterial infections and as a drug to prevent traveler's diarrhea. It can block the action of certain enzymes and as a result interfere with the bacteria's ability to make cell walls.